Get the Stockscreener App
2.15
4.44%
-0.10
After Hours:
2.20
0.05
+2.33%
Fate Therapeutics Inc stock is traded at $2.15, with a volume of 5.57M.
It is down -4.44% in the last 24 hours and up +61.65% over the past month.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
See More
Previous Close:
$2.25
Open:
$2.28
24h Volume:
5.57M
Relative Volume:
2.41
Market Cap:
$250.60M
Revenue:
$6.65M
Net Income/Loss:
$-136.32M
P/E Ratio:
-1.8733
EPS:
-1.1477
Net Cash Flow:
$-112.04M
1W Performance:
+13.76%
1M Performance:
+61.65%
6M Performance:
+95.45%
1Y Performance:
+85.34%
1-Day Range:
$2.09
$2.31
1-Week Range:
$1.785
$2.315
52-Week Range:
$0.91
$2.465
Fate Therapeutics Inc Stock (FATE) Company Profile
Name
Fate Therapeutics Inc
Sector
Industry
Phone
858.875.1803
Address
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Compare FATE vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FATE
Fate Therapeutics Inc
|
2.15 | 262.26M | 6.65M | -136.32M | -112.04M | -1.1477 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Oct-27-25 | Upgrade | Wedbush | Neutral → Outperform |
| Nov-18-24 | Upgrade | BofA Securities | Underperform → Neutral |
| Jun-17-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-27-23 | Resumed | Wells Fargo | Equal Weight |
| Jan-24-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | BofA Securities | Buy → Underperform |
| Jan-06-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-06-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-06-23 | Downgrade | Stifel | Buy → Hold |
| Jan-06-23 | Downgrade | Truist | Buy → Hold |
| Jan-06-23 | Downgrade | Wedbush | Outperform → Neutral |
| Jan-03-23 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-22-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-15-22 | Initiated | Goldman | Sell |
| Nov-04-22 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-10-22 | Initiated | Canaccord Genuity | Buy |
| Aug-18-22 | Resumed | Wells Fargo | Overweight |
| Jul-28-22 | Initiated | Needham | Hold |
| Jul-11-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-03-22 | Initiated | Robert W. Baird | Neutral |
| Feb-11-22 | Resumed | BMO Capital Markets | Market Perform |
| Dec-15-21 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-07-21 | Initiated | Cowen | Outperform |
| Nov-09-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-26-21 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-07-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| May-07-21 | Upgrade | Wedbush | Neutral → Outperform |
| Apr-26-21 | Resumed | Jefferies | Buy |
| Feb-26-21 | Initiated | BofA Securities | Buy |
| Feb-26-21 | Downgrade | Wedbush | Outperform → Neutral |
| Feb-11-21 | Downgrade | Citigroup | Buy → Neutral |
| Jan-27-21 | Resumed | H.C. Wainwright | Neutral |
| May-13-20 | Initiated | H.C. Wainwright | Buy |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-09-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-30-19 | Reiterated | Mizuho | Buy |
| Dec-09-19 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Nov-06-19 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Oct-01-19 | Initiated | Stifel | Buy |
| Aug-09-19 | Initiated | BTIG Research | Buy |
| Jul-22-19 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-12-19 | Initiated | Oppenheimer | Outperform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Jun-07-19 | Initiated | ROTH Capital | Neutral |
| May-31-19 | Initiated | Guggenheim | Buy |
| May-24-19 | Resumed | Citigroup | Buy |
| Mar-28-19 | Initiated | SVB Leerink | Outperform |
| Jan-03-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-05-18 | Initiated | Jefferies | Buy |
| Aug-01-18 | Initiated | Citigroup | Buy |
| Mar-06-18 | Downgrade | H.C. Wainwright | Buy → Neutral |
View All
Fate Therapeutics Inc Stock (FATE) Latest News
BofA Securities Maintains Fate Therapeutics(FATE.US) With Hold Rating, Raises Target Price to $2.2 - Moomoo
FATE Stock Price, Quote & Chart | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares - Investing.com UK
Fate therapeutics CEO Bahram Valamehr sells $54,482 in shares By Investing.com - Investing.com Australia
Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction - Stock Titan
Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale - Stock Titan
Fate Therapeutics to present CAR T-cell therapy data at medical conferences - StreetInsider
Fate Therapeutics to present CAR T-cell data at medical conferences - Investing.com
Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR - Stock Titan
Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential - Investing.com India
[144] FATE THERAPEUTICS INC SEC Filing - Stock Titan
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets - TradingView
Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential By Investing.com - Investing.com South Africa
Jefferies Initiates Fate Therapeutics(FATE.US) With Buy Rating, Announces Target Price $4 - Moomoo
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill
Needham Maintains Fate Therapeutics(FATE.US) With Hold Rating, Announces Target Price $2.25 - Moomoo
Fate Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
Fate Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Key Disclosures - Minichart
Fate Therapeutics earnings beat by $0.02, revenue topped estimates - Investing.com Canada
FT819 Remodels Lupus B Cells in Clinical Trial - CRISPR Medicine News
Fate Therapeutics Reports Q1 2026 Financial Results, Advances FT819 and FT839 CAR T-Cell Trials with Extended Cash Runway into 2028 - Minichart
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Fate Therapeutics (NASDAQ: FATE) narrows Q1 2026 loss as R&D costs fall - Stock Titan
Fate Therapeutics 1Q 2026: Revenue $1.3M, EPS $(0.26) — 10-Q Summary - TradingView
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates - The Manila Times
Fate Therapeutics Q1 operating loss narrows, cash runway extended into 2028 - TradingView
Fate Therapeutics: Q1 Earnings Snapshot - KTVB
Fate Therapeutics reports Q1 2026 net loss $31.2M, cash and investments $174.8M; runway into 2028 - TradingView
Fate Therapeutics (NASDAQ: FATE) trims Q1 loss, extends cash runway and advances FT819 - Stock Titan
Fate: 'Hold' FT819 Regimen B Dosing And Potential FDA Alignment In H2 2026 (NASDAQ:FATE) - Seeking Alpha
FATE SEC FilingsFate Therapeutic 10-K, 10-Q, 8-K Forms - Stock Titan
Fate Therapeutics presents CAR T-cell therapy data at ASGCT - Investing.com UK
Fate Therapeutics presents CAR T-cell therapy data at ASGCT By Investing.com - Investing.com South Africa
Fate Therapeutics Showcases FT819 Clinical Activity in SLE - GlobeNewswire
Fate Therapeutics (FATE) Eps Diluted (TTM) - Zacks Investment Research
Number of shareholders of Fate Therapeutics, Inc. – NASDAQ:FATE - TradingView
MSN Money - MSN
FATE Technical Analysis | Trend, Signals & Chart Patterns | FATE THERAPEUTICS INC (NASDAQ:FATE) - ChartMill
Fate Therapeutics Inc (FATE) Stock Price Today & Analysis - Gotrade
Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k shares - Stock Titan
Fate Therapeutics Inc (FATE) News, Articles, Events & Latest Updates - Stocktwits
Director at Fate Therapeutics (NASDAQ: FATE) exercises 25,000 stock options - Stock Titan
FATE Therapeutics (NASDAQ: FATE) director exercises options, boosts direct stake - Stock Titan
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6 - Moomoo
HC Wainwright Issues Positive Estimate for FATE Earnings - MarketBeat
H.C. Wainwright Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $7 - Moomoo
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program By Investing.com - Investing.com India
Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday - MarketBeat
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program - Investing.com
Fate Therapeutics selected for U.S. FDA chemistry, manufacturing, and controls development and readiness pilot program to support manufacturing readiness of FT819 - marketscreener.com
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819 - The Manila Times
Fate Therapeutics Inc Stock (FATE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):